MiR-338–5p, a novel metastasis-related miRNA, inhibits triple-negative breast cancer progression by targeting the ETS1/NOTCH1 axis

• Published in: Heliyon Vol. 10; no. 15; p. e34949
• Main Authors: Chen, Wen-Jia, Ye, Qian-Qian, Wu, Hua-Tao, Wu, Zheng, Lan, Yang-Zheng, Fang, Ze-Xuan, Lin, Wen-Ting, Liu, Jing
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 15.08.2024; Elsevier
• Subjects: Breast cancer; ETS1; Metastasis; miR-338–5p; NOTCH1; Breast cancer; miR-338–5p; NOTCH1; Metastasis; ETS1
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e34949

Breast cancer ranks as the most prevalent cancer globally, surpassing lung cancer, with recurrence/metastasis to be its main account for the cancer-related mortality. MicroRNAs (miRNAs) participate critically in various physiological and pathological processes through posttranscriptional regulation of downstream genes. Our preliminary findings identified miR-338–5p, potentially linked to metastasis in breast cancer, a previously unexplored area. Analysis of the GSE38867 dataset revealed the decreased miR-338–5p expression in metastatic breast cancer compared to normal tissues. Cellular function experiments and a xenograft tumor model demonstrated the inhibitory function of miR-338–5p on the progression of breast cancer in vitro and in vivo. Furthermore, it downregulated the expression of mesenchymal biomarkers and NOTCH1 significantly. With the predicting targets of miR-338–5p and transcription factors of the NOTCH1 gene, coupled with dual luciferase reporter assays, it is identified ETS1 as the interactor between miR-338–5p and NOTCH1. In breast cancer tissues, as well as in our xenograft tumor model, expression of ETS1 and NOTCH1 was positively correlated using immunohistochemical staining. This study reports, for the first time, on the miR-338–5p/ETS1/NOTCH1 axis and its pivotal role in breast cancer proliferation and metastasis. These findings propose a novel therapeutic strategy for breast cancer patients and lays a foundation for its clinical detection and treatment evaluation.